Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Matsumura, Yasufumi; Yamamoto, Masaki; Nagao, Miki; Komori, Toshiaki; Fujita, Naohisa; Hayashi, Akihiko; Shimizu, Takeshi; Watanabe, Hiroki; Doi, Shoichi; Tanaka, Michio; Takakura, Shunji; Ichiyama, Satoshi

doi:10.1128/aac.00701-15

Cited by 101 publications

(74 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, clinical data evaluating cephamycins for ESBL infections are scarce, and data comparing the relative efficacy of the various cephamycins are virtually nonexistent. Existing observational studies comparing cephamycins and carbapenems are plagued by the inherent limitations of observational studies-most notably confounding by indication-as well as small sample sizes (Table 2) [15][16][17][18][19][20]. Only 1 of these studies showed improved outcomes among ESBL-infected patients treated with carbapenems compared with cephamycins, while the others could not detect differences [18] (Table 3).…”

Section: Cephamycinsmentioning

confidence: 99%

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Tamma¹,

Rodríguez‐Baño

2017

Clinical Infectious Diseases

154

117

View full text Add to dashboard Cite

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.

show abstract

Section: Cephamycinsmentioning

confidence: 99%

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Tamma¹,

Rodríguez‐Baño

2017

Clinical Infectious Diseases

154

117

View full text Add to dashboard Cite

show abstract

“…Among ␤-lactam alternatives to carbapenems for the treatment of severe infections due to ESBL and OXA-1 producers, cephamycins (32) and temocillin are the most promising antibiotics. However, treatment of ESBL-producing K. pneumoniae by cefoxitin was associated with emergence of porin-deficient resistant mutants responsible for therapeutic failure and human death (33).…”

Section: Discussionmentioning

confidence: 99%

Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection

Rossi

Chau

Massias

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We investigated the efficacies of cefotaxime (CTX) and amoxicillin (AMX)-clavulanate (CLA) (AMC) against extended-spectrum-␤-lactamase (ESBL)-producingIn vivo, this antibiotic combination was similarly active against both strains and as effective as imipenem. In conclusion, the cefotaxime and amoxicillin-clavulanate combination appear to be an effective, easy, and already available alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains.

show abstract

“…16 In Japan, cefmetazole and flomoxef are commercially available cephamycins and are used commonly. 17 As noted here, a few, small studies examined the efficacy of cephamycins against ESBL infection. Ten adult patients with urinary tract infection (UTI) caused by an ESBL-producing Enterobacteriaceae who were treated with cefmetazole had the same treatment effect as those treated with carbapenems.…”

Section: Introductionmentioning

confidence: 99%

“…In severe ESBL‐producing bacterial infection, however, piperacillin/tazobactam is not generally recommended due to the higher mortality rate associated with its use . In Japan, cefmetazole and flomoxef are commercially available cephamycins and are used commonly . As noted here, a few, small studies examined the efficacy of cephamycins against ESBL infection.…”

Section: Introductionmentioning

confidence: 99%

Cefmetazole for extended‐spectrum β‐lactamase‐producing Enterobacteriaceae in pediatric pyelonephritis

Araki

Fukuoka

Handa

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background Pyelonephritis caused by extended‐spectrum β‐lactamase (ESBL)‐producing Enterobacteriaceae is an urgent problem in pediatrics. Although carbapenem is the standard therapy for infections caused by ESBL‐producing Enterobacteriaceae, some cephamycins, including cefmetazole, are stable against hydrolysis by ESBL. There are few reports, however, on the use of cefmetazole in children. The aim of this study was to evaluate the therapeutic effect of cefmetazole in pediatric pyelonephritis caused by ESBL‐producing Enterobacteriaceae. Methods Children with pyelonephritis caused by ESBL‐producing Enterobacteriaceae were enrolled between April 2010 and November 2016 at Tokyo Metropolitan Children's Medical Center. Presence of ESBL was tested for using the disk diffusion method. Medical records were reviewed for a past history of bacterial infection. The outcomes were clinical cure rate at 4 weeks and the duration of therapy in the cefmetazole and non‐cefmetazole groups. Results Fifty‐five patients met the criteria for pyelonephritis caused by ESBL‐producing Enterobacteriaceae. The most common causative organisms were Escherichia coli (n = 51; 92.7%), Klebsiella pneumoniae (n = 3; 5.5%), and K. oxytoca (n = 1; 1.8%). Thirty‐six and 19 patients were treated with cefmetazole and with other antibiotics as definitive therapy, respectively. There was no difference in the clinical cure rate (86.1% vs 89.5%; P = 0.72) or duration of therapy (median, 7.0 vs 7.0 days; P = 0.73) between the cefmetazole and non‐cefmetazole groups. Conclusions Cefmetazole was not inferior to the other antibiotics in the treatment of pyelonephritis caused by ESBL‐producing Enterobacteriaceae in children. Cefmetazole is a valuable therapeutic alternative to carbapenems for treating pyelonephritis caused by ESBL‐producing Enterobacteriaceae.

show abstract

Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Cited by 101 publications

References 24 publications

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection

Cefmetazole for extended‐spectrum β‐lactamase‐producing Enterobacteriaceae in pediatric pyelonephritis

Contact Info

Product

Resources

About